Another milestone for in vivo gene editing! YolTech Therapeutics' YOLT-202 receives FDA RMAT designation | Unity Ventures Portfolio
A promising "one-and-done" curative treatment for alpha-1 antitrypsin deficiency that could become the best-in-class therapy globally









